Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Human Vaccines Administered Orally
1.2 Key Market Segments
1.2.1 Human Vaccines Administered Orally Segment by Type
1.2.2 Human Vaccines Administered Orally Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Human Vaccines Administered Orally Market Overview
2.1 Global Market Overview
2.1.1 Global Human Vaccines Administered Orally Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Human Vaccines Administered Orally Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Human Vaccines Administered Orally Market Competitive Landscape
3.1 Global Human Vaccines Administered Orally Sales by Manufacturers (2019-2024)
3.2 Global Human Vaccines Administered Orally Revenue Market Share by Manufacturers (2019-2024)
3.3 Human Vaccines Administered Orally Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Human Vaccines Administered Orally Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Human Vaccines Administered Orally Sales Sites, Area Served, Product Type
3.6 Human Vaccines Administered Orally Market Competitive Situation and Trends
3.6.1 Human Vaccines Administered Orally Market Concentration Rate
3.6.2 Global 5 and 10 Largest Human Vaccines Administered Orally Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Human Vaccines Administered Orally Industry Chain Analysis
4.1 Human Vaccines Administered Orally Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Human Vaccines Administered Orally Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Human Vaccines Administered Orally Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Human Vaccines Administered Orally Sales Market Share by Type (2019-2024)
6.3 Global Human Vaccines Administered Orally Market Size Market Share by Type (2019-2024)
6.4 Global Human Vaccines Administered Orally Price by Type (2019-2024)
7 Human Vaccines Administered Orally Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Human Vaccines Administered Orally Market Sales by Application (2019-2024)
7.3 Global Human Vaccines Administered Orally Market Size (M USD) by Application (2019-2024)
7.4 Global Human Vaccines Administered Orally Sales Growth Rate by Application (2019-2024)
8 Human Vaccines Administered Orally Market Segmentation by Region
8.1 Global Human Vaccines Administered Orally Sales by Region
8.1.1 Global Human Vaccines Administered Orally Sales by Region
8.1.2 Global Human Vaccines Administered Orally Sales Market Share by Region
8.2 North America
8.2.1 North America Human Vaccines Administered Orally Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Human Vaccines Administered Orally Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Human Vaccines Administered Orally Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Human Vaccines Administered Orally Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Human Vaccines Administered Orally Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Merck
9.1.1 Merck Human Vaccines Administered Orally Basic Information
9.1.2 Merck Human Vaccines Administered Orally Product Overview
9.1.3 Merck Human Vaccines Administered Orally Product Market Performance
9.1.4 Merck Business Overview
9.1.5 Merck Human Vaccines Administered Orally SWOT Analysis
9.1.6 Merck Recent Developments
9.2 GSK
9.2.1 GSK Human Vaccines Administered Orally Basic Information
9.2.2 GSK Human Vaccines Administered Orally Product Overview
9.2.3 GSK Human Vaccines Administered Orally Product Market Performance
9.2.4 GSK Business Overview
9.2.5 GSK Human Vaccines Administered Orally SWOT Analysis
9.2.6 GSK Recent Developments
9.3 Sanofi
9.3.1 Sanofi Human Vaccines Administered Orally Basic Information
9.3.2 Sanofi Human Vaccines Administered Orally Product Overview
9.3.3 Sanofi Human Vaccines Administered Orally Product Market Performance
9.3.4 Sanofi Human Vaccines Administered Orally SWOT Analysis
9.3.5 Sanofi Business Overview
9.3.6 Sanofi Recent Developments
9.4 Lanzhou Institute
9.4.1 Lanzhou Institute Human Vaccines Administered Orally Basic Information
9.4.2 Lanzhou Institute Human Vaccines Administered Orally Product Overview
9.4.3 Lanzhou Institute Human Vaccines Administered Orally Product Market Performance
9.4.4 Lanzhou Institute Business Overview
9.4.5 Lanzhou Institute Recent Developments
9.5 Serum Institute
9.5.1 Serum Institute Human Vaccines Administered Orally Basic Information
9.5.2 Serum Institute Human Vaccines Administered Orally Product Overview
9.5.3 Serum Institute Human Vaccines Administered Orally Product Market Performance
9.5.4 Serum Institute Business Overview
9.5.5 Serum Institute Recent Developments
9.6 Valneva
9.6.1 Valneva Human Vaccines Administered Orally Basic Information
9.6.2 Valneva Human Vaccines Administered Orally Product Overview
9.6.3 Valneva Human Vaccines Administered Orally Product Market Performance
9.6.4 Valneva Business Overview
9.6.5 Valneva Recent Developments
9.7 Shanghai United Cell
9.7.1 Shanghai United Cell Human Vaccines Administered Orally Basic Information
9.7.2 Shanghai United Cell Human Vaccines Administered Orally Product Overview
9.7.3 Shanghai United Cell Human Vaccines Administered Orally Product Market Performance
9.7.4 Shanghai United Cell Business Overview
9.7.5 Shanghai United Cell Recent Developments
9.8 Bibcol
9.8.1 Bibcol Human Vaccines Administered Orally Basic Information
9.8.2 Bibcol Human Vaccines Administered Orally Product Overview
9.8.3 Bibcol Human Vaccines Administered Orally Product Market Performance
9.8.4 Bibcol Business Overview
9.8.5 Bibcol Recent Developments
9.9 PaxVax
9.9.1 PaxVax Human Vaccines Administered Orally Basic Information
9.9.2 PaxVax Human Vaccines Administered Orally Product Overview
9.9.3 PaxVax Human Vaccines Administered Orally Product Market Performance
9.9.4 PaxVax Business Overview
9.9.5 PaxVax Recent Developments
9.10 Vabiotech
9.10.1 Vabiotech Human Vaccines Administered Orally Basic Information
9.10.2 Vabiotech Human Vaccines Administered Orally Product Overview
9.10.3 Vabiotech Human Vaccines Administered Orally Product Market Performance
9.10.4 Vabiotech Business Overview
9.10.5 Vabiotech Recent Developments
9.11 Tiantan Biological
9.11.1 Tiantan Biological Human Vaccines Administered Orally Basic Information
9.11.2 Tiantan Biological Human Vaccines Administered Orally Product Overview
9.11.3 Tiantan Biological Human Vaccines Administered Orally Product Market Performance
9.11.4 Tiantan Biological Business Overview
9.11.5 Tiantan Biological Recent Developments
9.12 EuBiologics
9.12.1 EuBiologics Human Vaccines Administered Orally Basic Information
9.12.2 EuBiologics Human Vaccines Administered Orally Product Overview
9.12.3 EuBiologics Human Vaccines Administered Orally Product Market Performance
9.12.4 EuBiologics Business Overview
9.12.5 EuBiologics Recent Developments
9.13 Panacea Biotec Ltd
9.13.1 Panacea Biotec Ltd Human Vaccines Administered Orally Basic Information
9.13.2 Panacea Biotec Ltd Human Vaccines Administered Orally Product Overview
9.13.3 Panacea Biotec Ltd Human Vaccines Administered Orally Product Market Performance
9.13.4 Panacea Biotec Ltd Business Overview
9.13.5 Panacea Biotec Ltd Recent Developments
9.14 Bio-Med
9.14.1 Bio-Med Human Vaccines Administered Orally Basic Information
9.14.2 Bio-Med Human Vaccines Administered Orally Product Overview
9.14.3 Bio-Med Human Vaccines Administered Orally Product Market Performance
9.14.4 Bio-Med Business Overview
9.14.5 Bio-Med Recent Developments
9.15 Halfkin Bio-Pharmaceuticals
9.15.1 Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Basic Information
9.15.2 Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Product Overview
9.15.3 Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Product Market Performance
9.15.4 Halfkin Bio-Pharmaceuticals Business Overview
9.15.5 Halfkin Bio-Pharmaceuticals Recent Developments
10 Human Vaccines Administered Orally Market Forecast by Region
10.1 Global Human Vaccines Administered Orally Market Size Forecast
10.2 Global Human Vaccines Administered Orally Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Human Vaccines Administered Orally Market Size Forecast by Country
10.2.3 Asia Pacific Human Vaccines Administered Orally Market Size Forecast by Region
10.2.4 South America Human Vaccines Administered Orally Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Human Vaccines Administered Orally by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Human Vaccines Administered Orally Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Human Vaccines Administered Orally by Type (2025-2030)
11.1.2 Global Human Vaccines Administered Orally Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Human Vaccines Administered Orally by Type (2025-2030)
11.2 Global Human Vaccines Administered Orally Market Forecast by Application (2025-2030)
11.2.1 Global Human Vaccines Administered Orally Sales (Kilotons) Forecast by Application
11.2.2 Global Human Vaccines Administered Orally Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings
